Director Declaration

RNS Number : 7283P

Epistem Holdings plc

30 March 2009

 

For release: 30 March 2009

Epistem Holdings Plc ('the Company')

Director's Transactions

Epistem (AIM: EHP) announces that today it was notified that David Evans, Chairman, has today transferred 40,000 ordinary shares of 1.5 pence each ('Ordinary Shares') to his pension fund managed by Alliance Trust. Following this transfer, Mr. Evans' beneficial interest remains unchanged at 80,645 Ordinary Shares, being 1.11% of the Company's issued share capital.   

For further details, please contact:

Epistem Plc

Matthew Walls CEO                                            [phone]

Piper Jaffray Ltd.

Neil Mackison / James Steel                                [phone]

Corporate Broking: Jamie Adams

Mike Wort / Anna Dunphy                                    [phone]

De Facto Communications

Notes to Editors:

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

 

END

 

 

RDNJMMITMMTJBBL